A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

In this population-based cohort study, patients with type 2 diabetes who received glucagon-like peptide-1 receptor agonists had a higher risk of developing gastroesophageal reflux disease and ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased ...

In older patients with cancer and type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with ...

As GLP-1-based drugs like semaglutide gain popularity, new insights highlight how gut health, diet, protein, and sleep can ...

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

USA: Researchers have found in a new study that patients with idiopathic intracranial hypertension (IIH) treated with ...

People with type 2 diabetes were more likely to suffer from gastroesophageal reflux disease (GERD) if they were prescribed a ...

Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...

The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...

Learn how the benefits of GLP-1s may be outweighed by the risks.

Folks on GLP-1 drugs can expect to maintain their weight loss if they have a disruption in access, as long as they’ve also ...